Neoadjuvant immunotherapy is named as an intervention in 4 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Fudan University (1). The most-studied condition is Resectable Stage II-IIIa NSCLC.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
NCT07554846 · ClinicalTrials.gov ↗ · Resectable Stage II-IIIa NSCLC
|
Phase 3 | Recruiting | Fudan University | China |
|
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
NCT06926179 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy
|
Observational | Recruiting | Peking University Cancer Hospital & Institute | China |
|
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
NCT07050524 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III
|
Phase 2 | Not yet open | The First Affiliated Hospital with Nanjing Medical University | China |
|
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
NCT06762158 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)
|
Not applicable | Active, closed | RenJi Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Fudan University | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| RenJi Hospital | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 2 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Neoadjuvant immunotherapy as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Fudan University (1), The First Affiliated Hospital with Nanjing Medical University (1), RenJi Hospital (1) and Peking University Cancer Hospital & Institute (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Neoadjuvant immunotherapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Neoadjuvant immunotherapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Neoadjuvant immunotherapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.